MPT is provided as a sequence of low-energy electrical pulses to restore a normal heartbeat. Credit: StockSnap / Pixabay.

Cardialen has obtained approval from the the US Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) to commence clinical trial of its MultiPulse Therapy (MPT) for the treatment of paroxysmal and persistent atrial fibrillation (AF).

The low-energy MPT is intended to use the latest implantable device technologies to treat tachycardia and fibrillation.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It is provided as a sequence of low-energy electrical pulses to return irregular rapid heartbeats, such as AF, to a normal rate.

The company believes that this method of electrical pulse delivery will potentially be less painful for the patient.

The latest FDA approval will allow the company to begin a clinical study to assess the therapy’s performance and safety in paroxysmal and persistent AF patients.

Cardialen said that this trial builds on its previous study as well as a companion study that is currently enrolling participants across seven medical centres in Australia.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Ohio State University Wexner Medical Center lead clinical researcher, and principal investigator of the study, Dr John Hummel said: “We are excited to be contributing to Cardialen’s ongoing development of this AF therapy.

“I believe MPT has the potential to improve heart failure outcomes in patients suffering from AF and receiving a cardiac resynchronisation therapy defibrillator (CRT-D) implant.”

AF is an irregular and rapid heartbeat that can lead to discomfort, risk of stroke and other heart-related complications in patients.

According to Cardialen, about 36% of CRT-D patients and 26% of implantable cardioverter defibrillator (ICD) patients have, or are expected to experience, AF.

In October 2018, Cardialen raised $17m funding in a series B investment round led by RiverVest Venture Partners to develop an implantable defibrillation therapy for restoring normal heart rhythm.